# Clinical trials of antithrombotics for stable angina in all type of patient

**TrialResults-center** www.trialresultscenter.org

## 1 aspirin

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| **aspirin vs placebo** | | | |
| SAPAT , 1992<br>n=1009/1026<br>follow-up: 50 months | aspirin 75 mg daily<br>versus<br>placebo | patients with stable chronic angina pectoris | Parallel groups<br>double blind<br>Sweden |

### References


**SAPAT, 1992:**

Juul-Mller S, Edvardsson N, Jahnmatz B, Rosn A, Srensen S, Omblus R Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5 [1360557]




## 2 clopidogrel

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| **clopidogrel vs aspirin** | | | |
| ASCET<br>[NCT00222261]<br>n=498/503<br>follow-up: | clopidogrel 75 mg once daily for two years<br>versus<br>Aspirin 160 mg once daily for two years | patients with documented coronary heart disease and treated with aspirin | Parallel groups<br>open |

### References


**ASCET, :**


## 3 dipyridamol

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| **dipyridamol vs control** | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| Atlanta (Sbar) , 1967<br>n=30/30<br>follow-up: 6 months | dipyridamole 150mg daily<br>versus<br>placebo | patients with angina pectoris | parallel groups<br>double-blind |
| Wirecki , 1967<br>n=28/28<br>follow-up: 7 months | dipyridamole 150mg daily<br>versus<br>placebo | patients with angina pectoris | parallel groups<br>double blind |
| Becker , 1967<br>n=14/13<br>follow-up: 5 months | dipyridamole 225mg daily<br>versus<br>placebo | - | parallel groups<br>double-blind |
| **dipyridamol vs placebo** | | | |
| Kinsella , 1962<br>n=13/13<br>follow-up: 0.5 months | dipyridamole 37.5 mg and 100mg daily<br>versus<br>placebo | - | parallel groups<br>double-blind |
| Leiberman , 1964<br>n=19/19<br>follow-up: >3 months | dipyridamole 100mg daily<br>versus<br>placebo | - | parallel groups<br>double blind |
| Zion , 1961<br>n=14/14<br>follow-up: 0.5 months | Dipyridamole 37.5mg<br>versus<br>placebo | patients with angina pectoris | cross-over<br>double-blind |
| Dewar , 1961<br>n=17/17<br>follow-up: 0.5 months | Dipyridamole 100mg daily<br>versus<br>placebo | patients with angina pectoris | parallel groups<br>double-blind |
| Neumann , 1964<br>n=20/16<br>follow-up: 1.5 months | dipyridamole 150mg daily<br>versus<br>placebo | elderly with precordial pain | parallel groups<br>double-blind |
| Foulds , 1960<br>n=24/24<br>follow-up: 1 months | Dipyridamole 200mg daily<br>versus<br>placebo | patients with angina pectoris | parallel groups<br>double-blind |
| Igloe , 1970<br>n=26/22<br>follow-up: 2-7 months | Dipyridamole 200mg daily<br>versus<br>placebo | patients with angina pectoris | parallel groups<br>double blind |



## References

**Atlanta (Sbar), 1967:**

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

**Wirecki, 1967:**

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

**Becker, 1967:**

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

**Kinsella, 1962:**

KINSELLA D, TROUP W, McGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

**Leiberman, 1964:**

LEIBERMAN A, GUGLIELMELLI S PERSANTIN– A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

**Zion, 1961:**

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

**Dewar, 1961:**

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

**Neumann, 1964:**

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

**Foulds, 1960:**

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

**Igloe, 1970:**

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

# 4 oral platelet GP IIbIIIa receptor inhibitor

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| **roxifiban vs placebo** | | | |
| Murphy , 2003<br>n=120<br>follow-up: 30 days | roxifiban 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days<br>versus<br>placebo | patients with stable coronary artery disease | Parallel groups<br>double blind |



## References

**Murphy, 2003:**

Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs 2003;3:101-12 [14727937]

# 5 ticlopidine

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---|
| **ticlopidine vs placebo** | | | |
| Berglund , 1985<br>n=21/17<br>follow-up: 2m | ticlopidine 500 mg daily<br>versus<br>placebo | middle-aged men with stable incapacitating angina pectoris | parallel groups<br>double blind |

## References

**Berglund, 1985:**

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [3911481]

# 6 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.